Cost, effectiveness, and cost-effectiveness

Circulation: Cardiovascular Quality and Outcomes

Volumn 2, Issue 1, 2009, Pages 49-54

  Diamond, George A ^a   Kaul, Sanjay ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness; Health policy; Medical economics

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE; HEALTH ECONOMICS; HUMAN; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HEALTH SERVICES RESEARCH; REPRODUCIBILITY; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED STATES;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; MODELS, ECONOMIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; UNITED STATES;

EID: 76249106465     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.108.793406     Document Type: Review

References (48)

1. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996; 276: 1172-1177. (Pubitemid 26329746)
2. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996; 276: 1253-1258. (Pubitemid 26337709)
3. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA. 1996; 276: 1339-1341.
4. Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decisionanalytical modeling. Health Technol Assess. 2005; 9: iii-iv, ix-xi, 1-158.
5. Neumann PJ. Using Cost-effectiveness Analysis to Improve Health Care: Opportunities and Barriers. Oxford University Press: New York; 2005.
6. Mark DB. Economics and quality of life after acute myocardial infarction: insights from GUSTO-I. J Thromb Thrombolysis. 1996; 3: 151-155.
7. Steinberg EP, Topol EJ, Sakin JW, Kahane SN, Appel LJ, Powe NR, Anderson GF, Erickson JE, Guerci AD. Cost and procedure implications of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 1988; 12 (suppl A) : 58A-68A.
8. Barnett PG, Chen S, Boden WE, Chow B, Every NR, Lavori PW, Hlatky MA. Cost-effectiveness of a conservative, ischemia-guided management strategy after non-Q-wave myocardial infarction: results of a randomized trial. Circulation. 2002; 105: 680-684.
9. Tsai AG, Glick HA, Shera D, Stern L, Samaha FF. Cost-effectiveness of a low carbohydrate diet and a standard diet in severe obesity. Obes Res. 2005; 13: 1834-1840.
10. U-King-Im JM, Hollingworth W, Trivedi RA, Cross JJ, Higgins NJ, Graves MJ, Gutnikov S, Kirkpatrick PJ, Warburton EA, Antoun NM, Rothwell PM, Gillard JH. Ann Neurol. 2005; 58: 506-515.
11. Lee TT, Solomon NA, Heidenreich PA, Oehlert J, Garber AM. Costeffectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med. 1997; 126: 657-658.
12. Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics. 2005; 115: 1675-1684.
13. Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med. 2005; 118: 625-635.
14. Hunink MG, Kuntz KM, Fleischmann KE, Brady TJ. Noninvasive imaging for the diagnosis of coronary artery disease: focusing the development of new diagnostic technology. Ann Intern Med. 1999; 131: 673-680. (Pubitemid 29517953)
15. Kuntz KM, Kent KC. Is carotid endarterectomy cost-effective? An analysis of symptomatic and asymptomatic patients. Circulation. 1996; 94: II194-II198. (Pubitemid 26363391)
16. Klarenbach SW, Pannu N, Tonelli MA, Manns BJ. Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease. Crit Care Med. 2006; 34: 1044-1051.
17. Jonsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics. 2004; 22 (suppl 4) : 5-10. (Pubitemid 40066088)
18. Tengs TO. Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health. 2004; 7: 70-78.
19. Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR III, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the costeffectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003; 115: 632-641. (Pubitemid 37505905)
20. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000; 132: 769-779. (Pubitemid 30317791)
21. Messori A, Trippoli S, Becagli P, Tendi E. Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and costeffectiveness evaluation. Anticancer Drugs. 1998; 9: 491-502. (Pubitemid 28346497)
22. Weintraub WS, Mahoney EM, Lamy A, Culler S, Yuan Y, Caro J, Gabriel S, Yusuf S; CURE Study Investigators. Long-term costeffectiveness of clopidogrel given fur up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 2005; 45: 838-845. (Pubitemid 40342806)
23. Kallmes DF, Kallmes MH. Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms. AJNR Am J Neuroradiol. 1997; 18: 1453-1462. (Pubitemid 30413960)
24. Rettig RA. Implementing the End-Stage Renal Disease Program of Medicare. R 2505-HCFA/HEW, September 1980.
25. Garber A. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Affairs. 2004; W4-284-W4-296. Available at content.healthaffairs.org/cgi/reprint/hlthaff.w4.284v1.pdf. Accessed December 14, 2008. (Pubitemid 39297576)
26. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997; 16: 1-31.
27. Hadorn DC. Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue. JAMA. 1991; 265: 2218-2225.
28. Tung R, Kaul S, Diamond GA, Shah PK. Drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med. 2006; 144: 913-919. (Pubitemid 46768132)
29. Kaul S, Shah PK, Diamond GA. As time goes by. Current status and future directions in the controversy over stenting. J Am Coll Cardiol. 2007; 50: 127-137. (Pubitemid 47002183)
30. Gaziano TA. Cardiovascular disease in the developing world and its cost effective management. Circulation. 2005; 112: 3547-3553.
31. Sculpher MJ, Petticrew M, Kelland JL, Elliott RA, Holdright DR, Buxton MJ. Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions. Health Technol Assess. 1998; 2: i-iv, 1-178. (Pubitemid 28510215)
32. O'Rourke RA. Cost-effective management of chronic stable angina. Clin Cardiol. 1996; 19: 497-501. (Pubitemid 26314292)
33. Skinner JS, Staiger DO, Fisher ES. Is technological change in medicine always worth it? The case of acute myocardial infarction. Health Aff. 2006; 25: w34-w47.
34. Executive Order 12866 Regulatory planning and review. Federal Register. 1993; 58: 51735.
35. Federal Highway Administration. Evaluation and determination for Federal-aid transportation projects that have a net benefit to a Section 4. (f) property. Federal Register. 2005; 70: 20618-20630.
36. Miller W, Robinson LA, Lawrence RS, eds. Committee to Evaluate Measures of Health Benefits for Environmental, Health, and Safety Regulation. Valuing Health for Regulatory Cost Effectiveness Analysis. The National Academies Press: Washington DC; 2006.
37. Combination Pharmacotherapy and Public Health Research Working Group. Combination pharmacotherapy for cardiovascular disease. Ann Intern Med. 2005; 143: 593-599.
38. Taylor AJ, Binderman J, Feuerstein I, Cao F, Brazaitis M, O'Malley PG. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors. Mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) Project. J Am Coll Cardiol. 2005; 46: 807-814.
39. American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Dallas, Tex: American Heart Association; 2005.
40. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy. Arch Intern Med. 2006; 166: 2307-2313.
41. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002; 360: 7-22.
42. Koch R. The 80/20 Principle. Doubleday: New York; 1998.
43. Statistical Abstract of the United States. Table 116. Deaths-Life Years Lost and Mortality Costs by Age, Sex, and Cause: 2000 and 2002. Washington, DC: U. S. Department of Commerce; 2006: 92.
44. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. Working Paper No. 4164, National Bureau of Economic Research, 1992.
45. Diamond GA, Denton TA. Alternative perspectives on the biased foundations of medical technology assessment. Ann Intern Med. 1993; 118: 455-464.
46. Phillips KA. Chen JL. Impact of the U. S. panel on cost-effectiveness in health and medicine. Am J Prev Med. 2002; 22: 98-105.
47. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med. 1982; 73: 883-888.
48. Szucs TD, Schwenkglenks M, Berger K, Karsch K. Costs and cost effectiveness of eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study. Z Kardiol. 2003; 92: 236-244.